Aligos Therapeutics Inc., a private biotechnology company focused on the development of targeted antiviral therapies, has entered into a collaboration and license agreement with KU Leuven, in particular its Centre for Drug Design and Discovery (CD3), to develop a coronavirus protease inhibitor as a potential therapeutic candidate to address the COVID-19 pandemic.   Principal investigator Johan Neyts, Ph.D., professor of virology, and his scientific staff at the Rega Institute, together with the ...